Evidence map›Paper›PMID 40330576›Full record

ArticleIDCases2025

Rezafungin for suppressive therapy of

Matthew A Stack, Luis Ostrosky-Zeichner, Rodrigo Hasbun, Sun O Park, Jessica Babic, Mona Kapadia

Abstract readCase Reports
In one paragraph

Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matthew A StackUniversity of Texas Health Science Center at Houston, USA.
Luis Ostrosky-ZeichnerUniversity of Texas Health Science Center at Houston, USA.
Rodrigo HasbunUniversity of Texas Health Science Center at Houston, USA.
Sun O ParkUniversity of Texas Health Science Center at Houston, USA.
Jessica BabicMemorial Hermann Hospital-Texas Medical Center, USA.
Mona KapadiaUniversity of Texas Health Science Center at Houston, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Case: The patient is a 57-year-old male with a past medical history most notable for heart failure with ischemic cardiomyopathy. The patient underwent LVAD placement and his post-LVAD placement clinical course was notable for recurrent Conclusions: Rezafungin is a promising new antifungal in the armamentarium of drugs for treatment of invasive candidiasis, notably

Indexed as

Candida aurisLVADLVAD-associated infectionsRezafunginSuppressive therapy

Identifiers

PMID40330576
PMCPMC12052687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.